CNBC's Angelica Peebles joins 'Squawk Box' to report on the company's quarterly earnings results. Registered dietician Abbey Sharp explains the best and worst foods to eat after the expiration date ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ... Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm ...

He has also received personal honoraria from Novo Nordisk, Eli Lilly ... as members of The Conversation AU. Obesity is linked to many common diseases, such as type 2 diabetes, heart disease ...

Meanwhile, Lilly also confirmed that it will start running a head-to-head cardiovascular outcomes trial for Trulicity and one of its pipeline diabetes candidates – dual GIP/GLP1 agonist ...

Trump did not retract his threat of economic coercion during the 45-minute phone conversation ... drugmaker Eli Lilly, makes the main active ingredient in its popular obesity and diabetes ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Patrik Jonsson is an executive vice president at Eli Lilly and president ... a 35-year Lilly veteran who got his start as a sales rep for the company in Sweden. For the past year, Jonsson has run ...

Tirzepatide is offered by Eli Lilly in two weight loss products. Firstly, there is Mounjaro, which is approved for managing type 2 diabetes. Secondly, there is Zepbound, which is approved for ...

Jan 8 (Reuters) - Eli Lilly's (LLY.N), opens new tab ... as well as losing weight. Zepbound and Lilly's other blockbuster diabetes drug, Mounjaro, belong to a class of drugs called GLP-1 agonists.

Eli Lilly spooked ... to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and global expansion of sales of its diabetes and weight loss ...